[Prevention and treatment of malignant syndrome in patients with Parkinson's disease].
This article summarizes the prevention and treatment of malignant syndrome (MS) in Parkinson's disease. MS is often induced by sudden withdrawal of levodopa. However, many other events can be responsible for the induction of MS, including concomitant infections, dehydration, hot weather, discontinuation of other antiparkinsonian drugs, and 'wearing off' phenomenon. MS should be suspected when the body temperature rises above 38 degrees C without an apparent cause. The early detection and its prompt commencement of treatment are essential for improving the prognosis of the disease. The treatment consists of ample intravenous fluid, cooling the body, antiparkinsonian drugs (particularly, levodopa and bromocriptine), dantrolene sodium, and antibiotics if infection is present.
Kuno
Sadako
S
National Center of Neurology and Psychiatry, Musashi Hospital.
D000978:Antiparkinson Agents / Q000008:administration & dosage*; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology* / Q000517:prevention & control* / Q000628:therapy; D010300:Parkinson Disease / Q000150:complications*; D013375:Substance Withdrawal Syndrome
D000978:Antiparkinson Agents